Lipid Profile Abnormalities in People Living with HIV and AIDS by Sasi Anand, D
  
75
LIPID PROFILE ABNORMALITIES IN PEOPLE 
LIVING WITH HIV AND AIDS 
 
  
 
 
 
 
 
 
 
 
 
 
 
Dissertation Submitted for 
M.D. DEGREE IN GENERAL MEDICINE 
BRANCH – I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
MARCH – 2008 
  
76
 
 
 
CERTIFICATE 
 
 
 
Certified that this dissertation entitled “LIPID PROFILE 
ABNORMALITIES IN PEOPLE LIVING WITH HIV AND AIDS” is a 
bonafide work done by D. SASI ANAND, Post Graduate Student of Internal 
Medicine, Institute of Internal Medicine, Madras Medical College,              
Chennai – 600 003, during the academic year 2005-2008. 
 
 
 
 
 
 
 
Director and Professor, 
Institute of Internal Medicine, 
Madras Medical College &  
Govt. General Hospital, 
Chennai – 600 003. 
Additional Professor, 
Institute of Internal Medicine, 
Madras Medical College &  
Govt. General Hospital, 
Chennai – 600 03. 
 
 
 
The Dean 
Madras Medical College & Government General Hospital, 
Chennai – 600 003. 
 
 
 
  
77
 
 
 
 
DECLARATION 
 
 
I solemnly declare that this dissertation entitled “LIPID PROFILE 
ABNORMALITIES IN PEOPLE LIVING WITH HIV AND AIDS” was 
done by me at Madras Medical College and Government General Hospital 
during 2005-2008 under the guidance and supervision of                    
Prof. M. JUBILEE, M.D. This dissertation is submitted to the Tamil Nadu 
Dr. M.G.R. Medical University towards the partial fulfilment of 
requirements for the award of M.D. DEGREE IN GENERAL MEDICINE                 
(BRANCH – I) 
 
 
 
 
 
 
 
 
Place:  
Date:         D. SASI ANAND 
 
 
 
 
 
  
78
 
ACKNOWLEDGEMENT 
 
 
At the outset I thank Prof.T. Kalaniti, M.D., Dean, Madras Medical 
College, for having  permitted me to use the hospital resources for the study. 
 
I am immensely grateful to Prof.P. Thirumalaikolundu 
subramaniam, M.D., Director and Professor, Institute of Internal Medicine, 
for his suggestions and encouragement. 
 
I express my deep gratitude to Prof.M. Jubilee, M.D., Additional 
Professor, Institute of Internal Medicine and Chief, for her inspiration, 
advice, comments, corrections and guidance in making this work complete. 
 
I am ever grateful to Prof.V.K. Rajamani, M.D., Additional 
Professor, Institute of Internal Medicine and Chief-in-charge, Anti-
Retroviral Therapy Centre, who has extended excellent guidance. 
 
I express my sincere thanks to Dr.S.E. Dhanasegaran, M.D, Dr. 
Muthuselvan, M.D., Dr.G.Usha, M.D., Asst. Professors of Internal 
Medicine for their help. 
 
I express my gratitude and thanks to the patients who were kind and 
co-operative during the course of study. 
 
 
  
79
 
 
 
TABLE OF CONTENTS 
 
 
SL.NO. CONTENTS PAGE NO. 
1 INTRODUCTION 1 
2 AIM AND OBJECTIVES 3 
3 MATERIALS AND METHODOLOGY 4 
4 REVIEW OF LITERATURE 11 
5 RESULTS AND OBSERVATION 30 
6 DISCUSSION 43 
7 CONCLUSION AND SUMMARY 50 
8 BIBLIOGRAPHY 51 
9 MASTER CHART 67 
10 PROFORMA 72 
 
 
  
1
 
 
INTRODUCTION 
 
After the advent of highly active antiretroviral therapy (HAART), 
persons infected with HIV live longer and have fewer opportunistic 
complications. 
 
Metabolic toxicity of HAART, particularly dyslipidaemia, is now 
emerging as a major cardiovascular concern in HIV infected individuals. 
 
Epidemiological datas suggest a link between HIV infection, HAART 
use and premature atherosclerosis. When HIV infected individuals are given 
the expected long term use of HAART, their Coronary Artery Disease 
(CAD) risk is likely to increase. 
 
Therefore, strategies to minimize the CAD risk in HIV-Positive 
persons have focussed on risk factor modification, particularly the treatment 
of dyslipidaemia and the use of lipid-favourable HAART regimens. 
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Considering the importance of Dyslipidaemia in HIV – infected 
individuals, an analysis of lipid profile abnormalities in this subset of 
patients was made. 
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AIM OF THE STUDY 
 
 
1) To find out the lipid abnormalities in HIV-infected patients before 
starting HAART. 
 
2) To find out the lipid abnormalities in HIV-infected patients on 
HAART (Stavudine + Lamivudine + Nevirapine) for atleast 1 year. 
 
3) To compare the prevalence of dyslipidaemia between these two 
groups. 
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MATERIALS AND METHODS 
 
 
PLACE OF THE STUDY 
This study was conducted at the Government General Hospital, 
Chennai. Patients admitted to the wards of Institute of Internal Mediine and 
ART Centre were the subjects of the study. 
 
PERIOD OF STUDY 
APRIL 2006 – AUGUST 2007 
 
DESIGN 
Prospective Study 
 
INCLUSION CRITERIA 
HIV – Positive Patients 
 
SAMPLE SIZE 
Group I – HIV Positive patients without HAART – 50 
Group 2 – HIV Positive patients on HAART – 50 (Stavudine + 
Lamivudine + Nevirapine) for atleast 1 year. 
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EXCLUSION CRITERIA 
 Patients with Diabetes Mellitus 
 Patients with Renal, liver and Autoimmune Diseases. 
 Patients on long term steroid therapy 
 Patients with thyroid disorders and long standing cholestasis 
 Obese patients and chronic alcoholics 
 Patients on drugs like Beta Blockers, Diuretics, Cyclosporine, 
estrogen, Growth hormone, Retinoids , etc. 
 
METHODOLOGY 
  HIV infected individuals admitted in the wards of Institute of Internal 
Medicine and ART Centre at Government General Hospital were chosen for 
the study. Random selection of patients were made in whom a detailed 
History and Clinical evaluation after getting an informed consent from the 
patients, were done. 
  
  The following investigations were done to all patients selected in  this 
study. 
  
6
1) Fasting lipid profile (Total cholesterol, Triglycerides, High Density 
Lipoprotein). 
2) Renal Function Test (Sugar, Urea, Creatinine, and Electrolytes) 
3) Liver Function Test (S.Bilirubin, SGOT, SGPT, SAP, Total 
Protein and Albumin) 
4) Complete Blood Count (Total Count, Differential Count, ESR, 
Hemoglobin, PCV and Platelets) 
5) Electrocardiogram and Chest X-Ray – PA view 
6) CD4 Count  
 
METHODOLOGY OF INVESTIGATIONS 
 HIV serology was done using microlisa kit. 
 CD4 count was done with Facs count (Automated Counter) 
manufactured by Becton and Dickinson. 
 Lipid profile analysis was done on serum obtained after 12 hours 
of  fasting. Total cholesterol, triglycerides and HDL-C are 
measured. 
 
Tests were done in a single laboratory by the same person. Therefore 
no interpersonal error was possible. 
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 The normal values of the parameters taken for the study were assessed 
and listed below. 
Total Cholesterol (TC) 
 Desirable TC is Less than 200mg/dl 
 Borderline high TC is from 200-239mg/dl 
 High TC is greater than or equal to 240mg/dl 
 
HDL Cholesterol (HDL-C) 
 Desirable HDL-C is greater than  or equal to 40mg/dl 
 Low HDL-C is less than 40mg /dl 
 
Triglycerides (TG)  
 Desirable Trigylcerides is less than 150mg/dl 
 Borderline high TG is from 150 to 199mg/dl  
 High TG is from 200 to 499 mg/dl 
 Very-high TG is greater than 500mg/dl 
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WHO CLINICAL STAGING (NATIONAL AIDS CONTROL 
ORGANISATION)  
• Stage I - Asymptomatic  
- Persistent generalised lymphadenopathy 
- Performance scale 1:asymptomatic normal activity. 
• Stage II - Wt. loss < 10% of body weight  
- Minor muco cutaneous manifestation  
(seborrheic dermatitis, fungal nail infection, recurrent oral 
ulcers, angular chelitis) 
- Herpes zoster (within last 5 years)  
Recurrent upper resp. infection (bacterial sinusitis)  
Performance scale 2: Symptomatic, normal activity. 
• State 3 - Wt loss > 10% body weight  
unexplained chronic diarrhoea >1 month unexplained fever 
(intermittent/continuous) > 1 month 
- Oral Thrush 
- Oral hairy leukoplakia 
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- Pulmonary TB within past 1 year. 
-  Severe bacterial infection (preumonia, pyomyositis) 
- Performance Scale 3:  bed ridden for <50% of day in last 1 
month. 
• Stage 4 - HIV wasting synd (>10% BW loss + Unexplained fever 
(or) Unexplained diarrhoea >1 month chronic weakness) 
- Pneumocystitis carnii pneumonia 
- Toxoplasmosis of brain 
- Cryptosporidiasis with diarrhoea >1 month 
- Cyptococcosis (extra pulmonary) 
- Cytomegalo viral disease of organ other tran liver, spleen 
and lymph node 
- Herpes simplex infection, Mucocutaneous >1month (or) 
visceral 
- Progressive multifocal leukoencephalopathy 
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- Disseminated endemic mycosis, histoplasmosis, 
Coccidiodomycosis 
- Candidiasis of oesophagus, trachea, bronchi lung 
- Atypical; Mycobacterial infection 
- Non typhoid salmonella septicaemia 
- Extra pulmonary tuberculosis  
- Lymphoma  
- Kaposi sarcoma 
- HIV encephalopathy 
- Performance scale 4: Bed ridden for >50% of day in last 1 
month. 
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REVIEW OF LITERATURE 
 
 
The occurrence of dyslipidaemia is well recorded in HIV-infected 
persons, even prior to treatment with HAART. High density lipoprotein 
(HDL) Cholesterol (HDL-C) and Low Density Lipoprotein (LDL) -
Cholesterol (LDL-C) are decreased in HIV-infected individuals compared 
with HIV –negative controls (1) Elevated triglyceride (TG) levels frequently 
occur in the advanced stages of HIV infection  (1-3) 
 
In recent years, clinicians observed elevated cholesterol and often 
markedly elevated triglyceride levels in HIV infected persons maintained on 
HAART. The dyslipidaemia was often associated with other metabolic 
abnormalities, including insulin resistance and lipodystrophy, characterized 
by accumulation of visceral fat, an enlarged dorsocervical fat pad, and 
atrophy of subcutaneous fat in face, buttocks and extremities. This  
constellation of findings has been termed the HIV-related lipodystrophy 
syndrome. In many ways, it resembles the rare congenital and autoimmune 
disease related lipodystrophy syndromes(4). 
 
  
12
HAART ASSOCIATED DYSLIPIDAEMIA 
Different HAART agents have different effects on the lipid profile (5).   
In the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study 
(in which HAART use is defined  on the basis of the agents the subjects 
were taking at the time of study enrolment), the prevalence of Total 
Cholesterol > 240mg/dl among persons treated with HAART that include a 
protease inhibitor (PI) non nucleoside reverse transcriptase inhibitor 
(NNRTI), or both were 22.8, 27 and 44.1% respectively (5, 6). The 
prevalence of HDL-C < 35mg/dl was 19.1, 27.1 and 23.8% respectively, and 
TG Levels >200mg/dl were recorded in 31.8, 40 and 54.3 respectively. 
 
Thus, in patients treated with combination of PI and NNRTI, 
dyslipidaemia is particularly common; an effect that has been seen in 
multiple studies that have included patients of different ethnicities (7, 8).  
Among NRTI, stavudine (d4T) appears to produce hyper lipidaemia more 
frequently than zidovuine (AZT) or tenofovir (TDF) (9). 
 
ASSOCIATION WITH PROTEASE INHIVITORS 
 PI – containing regimens, and particularly those containing ritonavir  
(RTV), are frequently associated with elevations in Total cholesterol (T-
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Cho), LDL-C and TG, and a decline in HDL-C levels (10, 11, 12).  The risk of 
hypercholesterolaemia among patients receiving RTV, Nelfinavir (NFV) and 
indinavir (IDV) was increased 20, 9 – and 9-fold, respectively compared 
with PI-unexposed patients. (10, 13). 
  
Atazanavir (ATV) does not appear to affect TG and T-Cho levels 
significantly (13).  RTV use is associated with higher levels of T-chol, T-
chol/HDL-C and TG compared with regimens containing IDV, NFV or 
amprenavir (10) Extreme hypertriglyceridaemia is seen almost exclusively in 
RTV-treated patients (14). Typically, it is rapidly reversible when RTV is 
replaced by another PI or an NNRTI (10). 
 
 HIV RNA Levels, CD4 Cell Count, and weight change were neither 
predictors of hyperlipidaemia not confounders of the relationship with PIS. 
In a longitudinal study, which examined time dependent factors in a 
multivariate analysis, the initiation of PIS was a strong independent 
predictor of hypertriglyceridemia (12). 
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 Finally, vergees et al demonstrated that adherence to a PI-containing 
HAART regimen was associated with  a greater likelihood of developing 
elevated LDL cholesterol and severe (>800mg/dl) hypertriglyceridemia (15). 
 
ASSOCIATION WITH NON-NUCLEOSIDE REVERSE – 
TRANSCRIPTASE INHIBITORS (NNRTIS) 
 
 The NNRTIs cause alterations in the lipid profiles, although generally 
to a lesser degree than has been observed with PIs. NNRTIs use is associated 
with substantial increases in HDL-C levels to a degree not generally seen 
with PIs. The lipid profile changes are somewhat different with efavirenz 
(EFV) and nevirapine (NVP)  in the DAD study (5).  Patients treated with 
EFV had a higher risk of elevated T-chol or TG. In a substudy of the 
randomized, prospective 2NN trial, both NVP and EFV were associated with 
an increase in HDL-c at 48 weeks but the HDL-C increase was significantly 
larger in the NVP group (42.5%) than in the EFV group (16). The increase 
of TG was smaller in the NVP group (20.1%) than in the eFV group (40%). 
Data from the swiss HIV Cohort study also indicates larger TG increases 
with EFV exposure, compare with NVP. 
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 In a longitudinal study, Efavirenz or indinavir given with NRTIs 
raised T-Chol levels with 4-8 weeks of therapy, but subjects who received 
both efavirenz plus indinavir experienced the greatest increases in the total 
cholesterol level (17). HDL – C also increased significantly among subjects 
receiving efavirenz. Containing regimens. In a direct comparison reported in 
abstract form, nevirapine recipients had smaller increases in TG levels, 
greater increases in HDL-C levels than did efavirenz recipients, although the 
differences were relatively small in magnitude (18). 
 
 Additional data are needed before any firm conclusios can be drawn 
regarding the relative tendencies of individual non-nucleoside analogues to 
alter lipid profiles. 
 
ASSOCIATION WITH NUCLEOSIDE REVERSE – 
TRANSCRIPTASE INHIBITORS (NRTIs) 
 
 There are many studies suggest that the fat redistribution has been 
observed in PI-naïve patients taking various combinations of NRTIs (19-25). 
And in a randomized trial, there was a higher incidence of lipodystrophy in 
patients receiving ritonavir, saquinavir, and stavudine  than in patients taking 
the 2 PIs alone (26). In 2 multivariable analyses of cross-sectional and 
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longitudinal data, the use of several NRTIs persisted as an independent risk 
factor for lipodystrophy (27, 28). Among the NRTIs, stavudine had the 
strongest and most consistent association with fat redistribution in many of 
these studies. 
 
 The association between NRTIs and dyslipidaemia is less ideal. A 
small cross sectional study found higher triglyceride level in patient taking 
stavudine (20). In a prospective but uncontrolled study, Galli et al. followed 
335 PI-naive patients taking 2 NRTIs for a median exposure of 748 days. 
10% of patients developed T-chol levels >250mg/dl, and 23% developed TG 
levels >200mg/dl (24). Exposure to stavudine in this cohort was associated 
with an increased risk of developing hypertriglyceridaemia.  
 
 To summarise, there are clear evidence supports an association 
between    PI exposure and dyslipidaemia. NRTIs may be associated with 
hypercholesterolemia and possibly milder hypertriglyceridaemia. However, 
to confirm the association of NNRTIs with dyslipidaemia, needs further 
datas. 
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KINETICS OF HAART – ASSOCIATED SERUM LIPID CHANGES 
 In comparative HAART trials, lipid changes are often recorded 
several months after starting or changing HAART (11). However serum lipid 
levels typically increase within a few weeks after HAART initiation, and 
elevated levels are sustained therafter (11, 12, 29). This is well documented in 
cohort studies of HIV – infected individuals (11, 12, 14) and in clinical PI trials 
(29).  Dyslipidaemia is often rapidly but only partially reversible when PIs are 
discontinued (30), and typically worsens within the weeks when PIs are 
combined with NRTIs (26) or NNRTI’s.  The development of 
hypertriglyceridaemia and impaired insulin sensitivity after short term PI 
treatment (31, 32, 33) stands in contrast to body fat – redistribution, which 
generally becomes apparent only after several months of treatment with PIs 
or NRTIs (34, 35). 
 
PATHOGENESIS OF HAART – ASSOCIATED DYSLIPIDAEMIA 
 HAART may result in a number of metabolic disturbances, including 
subcutaneous lipoatrophy, truncal fat accumulation, hepatic steatosis, 
dyslipidaemia, insulin resistance, glucose intolerance and Type 2 Diabetes 
Mellitus. The exact pathogenic relationship between dyslipidaemia to 
lipodystrophy and insulin resistance is as yet undefined . Both PIs and 
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NRTIs are associated with these abnormalities; NNRTIs may also contribute 
to dyslipidaemia, although their exact relation to lipodystrophy is unclear 
(36). 
 
 The mechanisms responsible for HAART – associated dyslipidaemia 
are not fully elucidated and may include several factors, including HIV 
infection itself, the type of HAART and the concomitant presence of 
lipodystrophy. Evidence for a complex genetic predisposition has also 
emerged. 
 
HIV Infection and Plasma Lipids 
 Hypertriglyceridaemia in association with low HDL-C and  LDL-C, 
was commonly observed in HIV-infected individuals before the HAART (1, 
37-40). Several studies have suggested the following factors as contributing to 
dyslipidaemia:  
 
 The apolipoprotein E (Apo E) Genotype,     
 Increased synthesis of VLDL, and  
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 Decreased clearance of TG-rich lipoproteins such as VLDL, 
intermediate density lipoproteins (IDL) and chylomicrons and their 
remnants (14, 41, 42). 
 
Both hypertriglyceridaemia and hypocholesterolemia are associated with 
progressive HIV disease. These lipid abnormalities, may, however, reflect a 
non-specific response to chronic infection, as indicated by the well – 
documented relationship between TG concentrations and levels of 
inflammatory cytokines such as IFN-α and –γ or TNF (38, 40, 42).  On the other 
hand, low concentrations in HDL – C in a symptomatic HIV –infected 
patients could be due to an elevated catabolic rate of apolipoprotein (APO) 
A1, the main protein component of HDL partiles (43). 
 
DYSLIPIDAEMIA IN HAART – TREATED INDIVIDUALS 
 Compared with HIV-infected control subjects, HAART treated HIV-
positive patients had a significantly increased basal lipolysis in the Fasting 
state. Inspite a modest but significant increase in the rate of intraadipocyte 
re-esterification, the net result was an increase in the release of .free fatty 
acids (FFAs) into the plasma pool and into other sites with the highest 
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capacities for energy uptake such as the liver, visceral fat and skeletal 
muscle (44). 
 
 In the liver, increased uptake of FFAs enhances the synthesis of 
ApoB, reduces the degradation of ApoB and increases the production of 
VLDL particles (45). 
 
 Increased transport of FFAs into skeletal muscle results in 
intramyocellular lipid deposition, which is strongly associated with insulin 
resistance and impaired glucose disposal (45, 46). 
  
  PIs may also negatively affect glucose tolerance by directly inhibiting 
glucose transporter – 4, a transport molecule integral to this process(47). 
Nevertheless, FFA-uptake is higher within visceral Fat deposits than skeletal 
muscle, perhaps due to increased sensitivity to lipoprotein lipase (LPL) 
activating hormones such on cortisol, in omental adipocytes. This 
preferential deposition of fat may be the reason for the development of 
visceral obesity in HAART related lipodystrophy. 
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 Carr and colleagnes have suggested the inhibition of LDL-receptor – 
related protein (LRP) an another mechanism of PI-associated dyslipidaemia 
(48). LRP is a hepatic receptor that plays a critical role in clearance of ApoE – 
containing particles that are rich in TGS, such as chylomicrons, VLDL and 
their remnants. However, this hypothesis remain to be substantiated (31, 49). 
 
 Elevated FFAs inhibit LPL – activity which is required for the 
clearance of VLDL, IDL and chylomicrons (50). 
 
 The impaired clearance of TG-rich particles occurs as  a result of 
inhibition of LPL activity due to: 
• Increased levels of Apo C3 associated with increased plasma 
FFAs,  
• Increased levels of Apo C3 associated with decreased activation of 
the heterodimer peroxisome proliferators – activated receptor – α 
(PPAR-α) retinoic acid receptor (RXR). (14, 51). 
 
In one model, PIs cause increased activity of sterol regulatory element 
binding protein (SREBP), which alters adipocyte differentiation and reduces 
leptin levels (52) . In hepatocytes, SREBP induces lipogenic genes, which 
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leads to increased hepatic very-low density lipoprotein production. The 
increased lipid levels and reduced leptin levels, in turn, cause insulin 
resistance, which further activates SREBP, then perpetuating the cycle. 
 
The role of NRTIs in the HIV-related lipodystrophy has been attributed 
to mitochondrial toxicity (53) but this hypothesis has been challenged. 
 
POSSIBLE MECHANISMS FOR HAART – ASSOCIATED 
DYSLIPIDAEMIA 
Increased hepatic TG and cholesterol 
synthesis. 
Increased Substrate delivery of 
FFA’s. 
Insulin resistance 
Increased levels of SREBP – IC  
Improved nutritional status 
Impaired clearance of TG-rich 
particles 
Inhibition of LPL activity due to:  
Increased levels of ApoC3 associated 
with increased plasma FFAs. 
Increased levels of ApoC3 associated 
with decreased RXR-PPAR – Alpha 
activity  
Inhibition of LRP receptors (?) 
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GENETIC FACTORS 
 A genetic predisposition could explain why hyperlipidaemia occurs in 
some but not all patients, despite similar exposure to HAART and 
comparable demographic, immunological and virological characteristics. 
Research attention has focussed primarily on the potential role of 
unfavourable allelic variants of ApoE and ApoC3. ApoE is instrumental in 
the transport and clearance of lipoprotein remnants from the blood stream. 
ApoC3 inhibits the activity of lipoprotein lipase, and thereby modulates 
lipolysis   and hepatic clearance of plasma TG. 
  
 Case reports have described HIV-infected patients who were ApoE ε2 
or ε4 carriers in whom severe hyperlipidaemia was triggered by the initiation 
of HAART (54). ApoE ε4 carriage was already been linked to 
hypertriglyceridaemia in advanced HIV infection in the pre-HAART era (41). 
A more recent report showed an association of hypertriglyceridaemia with 
variant alleles of ApoC3 in 60 men who all were treated with PI based 
HAART (51). TG levels were higher in carriers of three variant ApoC3 alleles 
than in carriers of one or two variant alleles. 
 
 An association of these ApoE and ApoC3 variants with 
hyperlipidaemia was recently reported in a longitudinal study of 329 HIV-
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infected patients in the swiss HIV cohort study (14).  The genetic variants 
were relatively common : 27.7% of  patients were carriers of variant alleles 
of ApoE (i.e., ε2 or ε4 alleles), 17.9% were carriers of all three variants of 
ApoE. 5.8% were carriers of variants of both ApoC3 and ApoE; and these 
patients were at risk for extreme and sustained hypertriglyceridaemia when 
exposed to RTV. The relative contribution of genotype and HAART to lipid 
levels was also evaluated. HAART containing a PI but no RTV, and RTV – 
containing HAART were associated with increases in non –HDL-C of 
0.29mmol/l (11mg/dl) and 0.65mmol/l (25mg/dl), respectively. The 
contribution of the ApoE ε4 allele was a non – HDL-C increase of 
0.27mmol/l (10.4mg/dl) ; that is, quantitatively similar to the non-HDL-C 
increasing effect of PI treatment (14). This study highlighted the issues of 
appropriate methodology and statistical power in genetic association studies. 
Longitudinal modeling (12) of lipid levels in large numbers of patients may 
represent the most powerful approach to quantitating the contributions of 
genotype and HAART to dyslipidaemia. Cross-sectional analyses of lipid 
levels at a single time point during HAART exposure may be underpowered 
to detect the genetic effects. (14) 
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CARDIOVASCULAR RISK IN HIV-INFECTED PERSONS 
 Several cases of premature coronary Heart Disease (CHD) have been 
reported in HIV patients with dyslipidaemia associated with HAART (56-61) . 
In a cross sectional study, HIV infected individuals had more femoral or 
carotid artery atherogenic plagues than controls. However most of these 
patients had 1 or more established CHD risk factors like smoking, Diabetes 
Mellitus, Hypertension etc. 
 
 A recent large cohort study showed higher age-adjusted rates of 
coronary Artery Disease in HIV infected individuals compared with HIV-
negative individuals (6-3 versus 2.9/1000 person – years, respectively) (62). 
 
  
The most  solid data linking HAART  exposure to an increased 
cardiovascular risk to date was provided by the DAD study. In the most 
recent analysis of DAD data, the adjusted risk of myocardial infarction (MI) 
was increased by 17% for each year of HAART exposure, 16-18% for each 
mmol/l increase in T-Chol, and 39-48% for each doubling of the TG 
concentration (63).  
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It is clear that the benefits of HAART by far outweighs the small, 
absolute increase in cardiovascular risk that is presumably attributable to 
HAART (64). In the DAD study, the risk of MI was 1.39/1000 patient years 
in those not exposed to HAART. The risk increased 2.53/1000 in those <1 
year of exposure, and 6.07/1000 in those exposed to >6 years of HAART. 
 
 The exact mechanisms by which premature atherosclerosis is 
mediated in HIV infected person is unclear. Support for direct pro-
atherogenic effects is provided by studies showing that HAART and HIV 
infection itself may induct endothelial dysfunction (65-67) , an early indicator 
of atherosclerosis associated with diminished vasodilatory properties of the 
endothelium. 
 
 A large proportion of HIV-infected individuals can be classified as 
being at high 10-year cardiovascular risk. Among 3199 HIV-infected 
patients evaluated in Spain in 2004, 10% of women and 29% of men were 
considered to be at either moderately high or high 10 year CAD risk (68). 
With the improved life expectancy since the introduction of HAART and the 
consequent ageing of the HIV-infected population, the number of patients at 
high cardiovascular risk is likely to increase. This has already been shown in 
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the DAD cohort, in which the proportion of patients at high risk increased 
from 36.2% in 2000 to 44.7% in 2003 (69). After adjusting for changes in 
cardiac risk factors, however, the MI risk was lower in 2003-2004 compared 
with 1999-2000. The exact  reasons for this decrease in MI risk are not yet 
clear. Several changes over time have been noted in the DAD cohort, 
including a decrease in PI use (2000:47.4%, 2003: 40.1%), an increase in 
NNRTI use (2000:32.6%, 2003: 38.5%), an increase in patient receiving 
lipid-lowering therapy (2000: 4.0%, 2003: 8.1%), and an increasing 
proportion of ex-smokers (2000: 15.7%, 2003: 24.9%). Such trends have 
also been recorded in other studies, and suggest that physician awareness of 
cardiovascular risk is increasing (62, 70, 71). In a large cohort study from 
California, the use of d4T decreased, and the use of ATV and lipid-lowering 
therapy increased during the study period (1996-2004) (62). More widespread 
use of lipid-lowering therapy in the most recent years and a tendency to use 
PIs more sparingly has also been noted in a study from Tennesse (72). In the 
French Aquitaine Cohort of HAART-treated patients, a decrease in the 
prevalence of smoking, decreased PI use and an increase in the use of lipid-
lowering medication was noted between 2000 and 2004, along with a 
significant decrease in the intimal media thickness (71). Although the effect 
on cardiac outcomes remains to be confirmed, each of these studies suggests 
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the feasibility and potential efficacy of interventions aimed at cardiovascular 
prevention in HIV-infected patients. 
 
EFFECTS OF SWITCHING ANTIVIRAL THERAPIES 
 The association of increased serum lipid levels with certain 
antiretroviral therapies had led to exchanging the potentially offending 
component for another drug. This switching strategy has the potential 
advantage of avoiding pharmacologic intervention for elevations in lipid 
levels. However, because of the multifactorial nature of dyslipidemia in HIV 
infection, abnormalities may not resolve simply by switching drugs. 
Switching from a PI to nevirapine or abacavir has generally resulted in an 
improvement in total cholesterol and triglyceride levels (73-81), whereas 
switching to efavirenz has produced less consistent results (82). These  trials 
have generally demonstrated persistent viral suppression for 6-12 months 
after switching regimens. 
 
 In patients with a favourable treatment history (i.e., no previous 
receipt of an NRTI-based regimen that was less than fully suppressive and 
no history of virologic rebound occurring while receiving treatment), 
switching from a potentially lipid level increasing PI to nevirapine or 
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abacavir may be preferable to a pharmacologic intervention with  a lipid-
lowering drug . In practice, however, many patients will have  already 
received NNRTI therapy or are extensively NRTI experienced. Studies 
comparing the effects of treatment switching to those of adding lipid-
lowering agents to ongoing successful therapy have not been reported. 
Clinicians will need to weigh the risks of new treatment-related toxicities 
and the possibility of virologic relapse when switching antiretroviral drugs 
to the risks of potential drug interactions and new treatment-related toxicities 
from lipid-lowering agents that are added to existing regimens. 
  
COMPLICATIONS OF HYPERTRIGLYCERIDAEMIA IN HIV – 
INFECTED PERSONS 
 
 Extremely high TG levels (>1000 mg/dl) are usually associated with 
fasting chylomicronemia and cause the ‘Chylomicronemia syndrome’, 
which includes Acute Pancreatitis, abdominal pain with normal pancreatic 
enzymes, memory loss, lipemia retinalis, and eruptive xanthomata (83) . In 
addition, non-alcoholic steatohepatitis is also reported. 
 
 Some patients suffer significant psychological morbidity related to 
their body habitus change. 
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RESULTS AND OBSRVATION 
 
AGE DISTRIBUTION 
Table No. 1  : Shows age distribution in Group 1 (n-50) 
Age Dyslipidaemia No Dyslipidaemia 
< 30 14 (60.9%) 9 (39.1%) 
30 – 40 15 (65.2%) 8 (34.8%) 
> 40 4 (100.0%) - 
Mean + SD 32+6 
Chisquare Test P = 0.31 
Table No. 2: Shows age distribution in Group 2 (n=50 
Age  Dyslipidaemia No Dyslipidaemia 
< 30 4 (100.0%) - 
30 – 40 27 (84.4%) 5 (15.6%) 
> 40 12 (85.7%) 2 (14.3%) 
Mean + SD 38+8 
Chisquare Test P = 0.70 
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 Majority of the patients in our study were between 30 and 40 years of 
age. Of the 23 patients, who were in the age group of 30 – 40 among Group 
1, 15(65.2%) had dyslipidaemia and, of the 32 patients, who were in the age 
group of 30-40 among Group 2, 27(84.4%) had lipid profile abnormaities. 
 
 
SEX DISTRIBUTION 
Table No. 3: Shows sex distribution in Group - 1 
Gender  Dyslipidaemia No Dyslipidaemia 
Male  16 (64%) 9 (36%) 
Female 17 (68%) 8 (32%) 
Total  33 (66%) 17 (34%) 
 
 
 
 
 
 
 
  
32
 
Table No. 4: Shows sex distribution in Group 2  
Gender Dyslipidaemia No Dyslipidaemia 
Male  29 (85.3% 5 (14.7%) 
Female 14 (87.5%) 2 (12.5%) 
Total  43 (86%) 7 (14%) 
 
 
 In our study the prevalence of dyslipidaemia was found to be more 
among females than males in both the groups  
 
CD4  DISTRIBUTION 
Table No. 5:  
CD4 Count Group 1 Group 2 
Mean 508.70 357.64 
Range 257-1208 17.882 
 
The CD4 count of  patients among Group 1 ranged from 257 to 1208 
with the mean of 508.70 and among Group 22 ranged from 17 to 882 with 
the mean of 357.64. 
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TOTAL CHOLESTEROL (TC) 
Table No. 6 
TOTAL CHOLESTEROL  Group 1 
Normal 40 (80.0%) 
Borderline High 9 (18.0%) 
High 1 ( 2.0%) 
Mean +  SD 176 + 27 
 
 
Table No. 7 
TOTAL CHOLESTEROL  Group 2 
Normal 36 (72.0%) 
Borderline High 8 (16.0%) 
High 6 ( 12.0%) 
Mean +  SD 180 + 55 
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Majority of patients among group 1 and 2 found to have normal  T.C. 
levels. Only 20% of patients among Group 1 and 28% of patients among 
Group 2 were found to have high T.C. levels. 
 
The mean total cholesterol level among  Group 1 was 176 + 27 and 
among Group – 2 was 180 + 55. The alterations in T.Cholesterol Level was 
not statistically  significant in both the groups. ( P = 0.15) 
 
 
HDL CHOLESTEROL (HDL-C) 
Table No. 8 
HDL CHOLESTEROL  Group 1 
Low 7 (14.0) 
Normal 42 (81.0%) 
Negative Risk Factor 1 (2.0%) 
Mean +  SD 41 + 3 
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Table No. 9 
HDL CHOLESTEROL  Group 2 
Low 8 (16.0%) 
Normal 42 (84.0%) 
Negative Risk Factor - 
Mean +  SD 43+5 
 
 
Majority of patients among Group 1 and 2 found to have normal 
HDL-Cholesterol level. Only 14.0% of patients among Group 1 and 16.0% 
of patients among Group 2 were found to have Low HDL-C levels. 
Surprisingly, one patient among Group 1 was found to have HDL-C level of 
60 which is considered as a negative risk factor for future cardiac events. 
 
 The mean HDL – C level among Group 1 was 41+3 and among Group 
2 was 43+5. The alteration in HDL – L levels were not statistically 
significant in both the groups (P=0.59) 
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TRIGLYCERIDES 
(p = 0.00) 
Table No. 10 
TRIGLYCERIDES Group 1 
Normal  19 (38.0%) 
Borderline High 21 (42.0%) 
High  10 ( 20.0%) 
Very High - 
Mean +  SD 180 +69 
 
 
Table No. 11 
TRIGLYCERIDES Group 2 
Normal  9 (18.0%) 
Borderline High 11 (22.0%) 
High  26 (52.0%) 
Very High 4 (8.0%) 
Mean +  SD 281+202 
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About 62.0% of patients among Group 1 and 82.0% of patients among 
Group 2 found to have high Triglyceride levels. 
 
 The mean Triglycerides level among Group 1 was 180+69 and among 
Group 2 was 281+202. Around 8.0% of patients among Group 2 found to 
have very high TG Levels.  
 
 The alteration in Triglyceride levels were statistically significant in 
both the groups  (P=0.00) 
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DYSLIPIDAEMIA 
 (p = 0.03) 
Table No. 12 
DYSLIPIDAEMIA Group 1 Group 2 
Yes 33 (66.0%) 43(86.0%) 
No 17 (34.0%) 7(19.0%) 
 
 66% of patients among Group 1 found to have altered lipid profile 
whereas among Group 2, 86.0% of patients found to have altered lipid 
profile confirming the relationship of HAART with dyslipidaemia. 
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WHO STAGEWISE DISTRIBUTION OF PATIENTS 
Table No. 13 
STAGE Group 1 Group 2 
I 34 (68.0% 14 (28.0%) 
II 16 (32.0%) 14 (28.0%) 
III  12 (24.0%) 
IV  10 (20.0%) 
Total 50 50 
 
 
 All the patients among Group 1 were in Stage I & II and many of the 
patients (56.0%) among Group 2 were in Stage I & II and 24.0% in Stage III 
& 20% in Stage IV. 
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CORRELATION OF WHO STAGING AND 
DYSLIPIDAEMIA 
 
Table No. 14 
P = 0.76 
Group – 1 
STAGE 
Dyslipidaemia  No Dyslipidaemia 
I 23 ( 67.6%) 11 (32.4%) 
II 10 ( 62.5%) 6 ( 37.5%) 
III   
IV   
ChI-square Test 
Table No. 15 
P = 0.61 
Group – 2 
STAGE 
Dyslipidaemia  No Dyslipidaemia 
I 13 (92.9%) 1 (7.1%) 
II 11 (78.6%) 3 (21.4%) 
III 11 (91.7%) 1 ( 8.3%) 
IV 8 (80.0%) 2 (20.0%) 
ChI-square Test 
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 Majority of patients in Stage I & II in both the groups were found to 
have more alterations in lipid profile. There was no statistically significant 
correlation of WHO staging with dyslipidaemia. 
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CORRELATION OF CD4 AND DYSLIPIDAEMIA 
 
Table No. 16 
DYSLIPIDAEMIA MEDIAN RANGE 
Yes 404 17,1208 
No 445 42,961 
 
Mann – Whitney Test 
 
 There was no statistically significant correlation of CD4 counts with 
dyslipidaemia. 
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DISCUSSION 
 
 
AGE 
 
 The mean age of patients in Group 1 was 32+6 and the mean age in 
Group 2 was 38+8. There was no statistical significance found between  Age 
and dyslipidaemia in both the groups. 
  
SEX DISTRIBUTION 
 
 In our study the prevalence of dyslipidaemia was found to be more 
among females than males in both the groups. But there was no statistically 
significant correlation found between gender and dyslipidaemia. 
 
There are no studies available to suggest the correlation of Age / 
Gender with dyslipidaemia in HIV – infected patients. 
 
 
 
  
44
TOTAL CHOLESTEROL 
 Majority of patients in our study were found to have normal 
T.Cholesterol levels in both the groups. Only 20% of patients in Group 1 and 
28% of patients in Group 2 were documented to have high T.Cholesterol 
levels. 
 
In our study, only 12.0% of patients among Group 2 were found to 
have T.Cholesterol level > 250mg% whereas in DAD study, the prevalence 
of T.Cholesterol > 240mg/dl among persons treated with HAART that 
include a NNRTI was 27% (5, 6). 
 
 Present Study DAD Study 
Prevalence of T.Cholesterol >250mg/dl 12.0% 27.0% 
 
In a another prospective, but uncontrolled study, Galli et al, followed 
335 PI naïve patients taking 2NRTI’s for a period of 748 days, 10% of 
patients developed T.Cholesterol level > 250mg/dl (24). 
 Present Study Galli et al 
Prevalence of T.Cholesterol >250mg/dl 12.0% 10% 
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HDL CHOLESTEROL 
 Majority of patients in our study were found to have normal HDL-C 
levels only 14% of patients among Group 1 and 16% among Group 2 were 
documented to have HDL-C <40mg/dl. 
 
Hypertriglyceridaemia in association with Low HDL-C was 
commonly observed in HIV infected patients before the HAART (1, 37-40). 
 
 In our study also, 14% of patients found to have HDL-C <40mg/dl in 
Group 1. 
 
 In our study, 16.0% of patients among Group 2 were found to have 
HDL-C <40mg/dl where as in DAD study, the prevalence of HDL-C 
<35mg/dl among persons treated with HAART that included a NNRTI was 
27.1% (5,6). 
 Present Study DAD Study 
Prevalence of HDL-C < 40mg/dl 16%  
Prevalence of HDL-C < 35mg/dl  27.1% 
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TRIGLYCERIDES 
 Majority of patients in our study were found to have high Triglyceride 
levels in both the groups (62% among Group 1 & 82% among Group 2) 
                                                                                                                                                
 In our study, the prevalence of Triglycerides > 200mg/dl were 20.0% 
among Group 1 and 60.0% among Group 2 whereas Galli et al, observed 
that the prevalence of TG> 200mg/dl was 23% in patients taking 2 NRTI’s 
(24).  
 Present Study Galli et al 
Prevalence of Triglycerides >200mg/dl 
in HIV infected patients on HAART 
(excluding PI) 
60% 23% 
 
 Hypertriglyceridaemia in association with Low HDL-C was 
commonly observed in HIV – infected persons before the HAART. In  our 
study also, 20%  (1, 37-40) of patients among Group 1 found to have elevated 
TG level >200mg/dl before starting HAART. 
 
 Both hypertriglyceridaemia and hypocholesterolemia are associated 
with progressive HIV disease. These abnormalities may be a non specific 
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response to chronic infection as indicated by the well-documented 
relationship between Triglycerides concentration and levels of inflammatory 
cytokines. (38, 40, 42). 
 
DYSLIPIDAEMIA 
 In our study 66% of patients among Group 1 and 86% of patients 
among Group 2 were found to have altered lipid profile in the form of 
elevated TG, Low HDL-C and elevated T.Cholesterol alone or combination 
of these abnormalities. 
 
 Hypertriglyceridaemia was the most common lipid profile 
abnormality detected in our study. 
 
 There was no major or significant alterations in T.Chol & HDL-C 
levels observed in both the groups, whereas Triglyceride level, was 
significantly altered in both the groups, more with Group 2. 
 
 In our study, Dyslipidaemia was defined as  alteration in any one of 
the three parameters namely T-Cholesterol, Triglyceride and HDL-c alone or 
combination of these abnormalities. 
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 The prevalence of Dyslipidaemia among Group 2 was significantly 
more than that of Group1 indicating the role of HAART on lipid profile 
alterations. 
 
 In our study, all the 50 patients in Group 2 were on 2 NRTI’s 
(Satvudine) and Lamivudine) and 1 NNRTI (Nevirapine) Thereore, a 
significant lipid profile abnormalities can also occur in PI-naïve HAART 
regimens. 
 
 Many studies have documented the role of protease inhibitors in lipid 
profile alterations. It was evident from our study that significant alterations 
in lipid profile can occur in PI-naïve  patients on NNRTI’s, NRTI’s or 
combination of  both. 
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CORRELATION OF WHO STAGE AND CD4 COUNT WITH 
DYSLIPIDAEMIA 
 
 
 In our study, there was no statistical significance observed between 
CD4 count,  WHO stage and dyslipidaemia. 
 
  A well conducted analysis  did not find associations of dyslipidaemia 
with indicators of HIV infection status such an CD4 lymphocyte count or 
HIV viral load (12, 24). 
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CONCLUSION 
 
 Hypertriglyceridaemia was the most common lipid profile 
abnormality in HIV-infected patients before HAART and after 
HAART. There is no significant alteration in T.Chol and HDL-C 
levels as such in both the groups. 
 The prevalence of Dyslipidaemia in HIV positive patients before 
starting HAART (Group 1) was 66.0% 
 The prevalence of Dyslipidaemia in HIV positive patients on HAART 
(which includes stavudine,  Lamivudine and nevirapine ) for atleast 1 
year was 86.0% which confirms the effect of HAART on lipid profile. 
 There was no significant correlation of WHO stage, CD4 count  with 
the alteration of lipid profile in both the groups. 
 Significant alteration in lipid profile can occur in PI-naïve patients on 
NRTI’s, NNRTI’s  or combination of both. 
 
 
 
  
51
BIBLIOGRAPHY 
 
1) GRUNFELD C, KOTLER DP, HAMADEH R, TIERNEY A, WANG 
J, PIERSON RN: Hypertriglyceridaemia in the acquired 
immunodeficiency syndrome.  Am. J. Med (1989) 86 (1) : 27-31. 
2) CONSTANS J, PELLEGRIN JL, PEUCHANT E et al: plasma lipids 
in HIV – infected patients: a prospective study in 95 patients. Eur. 
J.Clin. Invest (1994) 24(6): 416-420 
3) GRUNFELD C, FEINGOLD KR: Metabolic disturbances and wasting 
in the acquired immunodeficiency syndrome. N.Engl. J. Med (1992) 
327(5) : 329-337. 
4) Garg A. Lipodystrophies. Am.J.Med (2000):108:143-52. 
5) FONTAS E, VAN LF, SABIN CA et al: Lipid profiles in HIV – 
infected patients receiving combination antiretroviral therapy: are 
different antiretroviral drugs associated with different lipid profiles? J. 
infect Dis. (2004) 189(6): 1056-1074. 
6) FRIIS – MOLLER N, WEBER R, REISS P et al: cardiovascular 
disease risk factors in HIV patients – association with antiretroviral 
therapy. Results from the DAD study. AIDS (2003) 17(8) : 1179-1193 
  
52
7) DUNCOMBE C, KERR S, AVIHINGSANON A: Dyslipidaemia in 
an asian population following treatment for 2 years with 5 different 
protease inhibitor containing regimens: The HIV-NAT Cohort. 
Proceedings of the 12th conference of Retrovirus and opportunistic 
infections. Boston, MA, USA (2005) Abstract No. 847. 
8) ROSENKRANZ SL, YARASHESKI K, PARA M: Lipid and 
lipoprotein changes during short term protease inhibitor and efavirenz 
exposure in HIV- Seronegative subjects. Proceedings of the 12th 
conference on Retroviruses Abstract No. 846. 
9) GALLANT JE, STASZEWSKI S, POZNIAK AL et al: Efficacy and 
safety of tenofovir DF versus stavudine in combination therapy in 
antiretrovirual naïve patients: a 3-year randomized trial JAMA (2004). 
10) PERIARD D, TELENTI A, SUDRE P et al: Atherogenic 
dyslipidaemia in HIV – infected individuals treated with protease 
inhibitors. The swiss HIV cohort study: circulation (1999) 100 (7): 
700-705. 
11) TSIODRAS S, MANTZOROS C, HAMMER S, SAMORE M: 
Effects of protease inhibitors on hyperglycemia, hyper lipidaemia and 
lipodystrophy: a 5 year cohort Study.Arch.Intern.Med (2000) 160 
(13): 2050-2056. 
  
53
12) THIEBAVT R, DABIS F, MALVY D, JACQMIN – GADDA H, 
MERCIE P, VALENTIN VD: serum triglycerides, HIV infection, and 
highly active antiretroviral therapy, Aquitaine cohort, France, 1996 to 
1998. Group d’ Epidemiologic clinique du sida en Aquitaine 
(GECSA) .J. Acquire. Immune. Defic.Syndr (2000) 23(3): 261-265. 
13) MURPHY RL, SANNE I, CAHN P et al: Dose – ranging, 
randomized, clinical trial of atazanavir with lamivudine and stavudine 
in antiretroviral naïve subjects: 48week results . AIDS (2003) 17 (18) 
: 2603-2614. 
14) TARR PE, TAFFE P, BLEIBER G et al modeling the influence of 
APOC3, APOE, and TNF Polymorphisms on the risk of antiretroviral 
therapy associated lipid disorders .j. infect Dis (2005) 191 (9): 1419-
1426. 
15) Vergis EN, Paterson DL, wagener MM, Swindells S, Singh N, 
Dyslipidaemia in HIV –infected patients; association with adherence 
to potent anti-retroviral therapy. Int. J STD AIDS 2001; 12: 463-8. 
16) VAN LF, PHANUPHAK P, STROES E et al: Nevirapine and 
efavirenz elicit different changes in lipid profiles in anti-retroviral – 
therapy – naïve patients infected with HIV-1. Plos Med. (2004)                  
1(1) : e 19. 
  
54
17) Tashima K, Stryker R, Skiest D, et al Lipid profiles and clinical 
lipodystrophy in study 006 patients (abstract 1304). In: 39th 
Interscience conference on Antimicrobial Agents and chemotherapy 
(San Diego) Washington, DC: American Society for microbiology, 
1999. 
18) Van leth F, Phanuphak P, Gazzard B, et al. Lipid changes in a 
randomized comparative trial of First-line antiretroviral therapy with 
regimens containing either nevirapine alone, efavirenz alone or both 
drugs combined, together with stavudine and lamivudine (2NN study) 
(abstract 752). In: program and abstracts of the 10th conference on 
Retroviruses and opportunistic infection (Boston) Alexandria, VA: 
Foundation for Retrovirology and Human Health, 2003:328. 
19) Boufasa F, Dulioust A, Lascaux As, et al Lipodystrophy in 685 HIV-1 
treated patients Influence of anti-retroviral treatment and 
immunovirological response. HIV Clin Trials 2001; 2:339-45. 
20) Saint- Marc T, partisani M, poizot – Martin I, et al A syndrome of 
peripheral fat wasting (lipodystrophy) in patients receiving long-term 
nucleoside analogue therapy AISS. 1999;13:1659-67. 
  
55
21) Madge S, Kinloch-de-Loes S, mercey D, Johnson MA, Waller. 
Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS 
1999; 13:735-7. 
22) Lo Jc, Mulligan K, Tai VW, Algren H, Schambelan M. “Buffalo 
Hump” in men with HIV-1 infection. Lancet 1998; 351:867-70. 
23) Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, viard JP. 
Lipodystrophic syndromes and hyperlipidaemia in a cohort of HIV-
infected patients receiving triple combination antiretroviral therapy 
with a protease inhibitor J Acquir Immune Defic Syndr 2001;27; 443-
9. 
24) Galli M, Ridolfo AL, Adorni F, et al Body habitus changes and 
metabolic alterations in protease inhibitor – naïve HIV -1-infected 
patients treated with two nucleoside reverse transcriptase inhibitors. J 
Acquir Immune Defic Syndr. 2002; 29: 21-31. 
25) Bogner JR, Vielhauer V, Beckmann RA, et al stavudine Versus 
zidovudine and the development of lipodystrophy J Acquir Immune 
Defic Syndr 2001; 27: 237-44. 
26) Van der valk M, Gisolf EH, Reiss P, et al. Increased risk of 
lipodystrophy when nucleoside analogue reverse transcriptase  
  
56
inhibitors are include with protease inhibitors in the treatment of HIV-
1 infection AIDS 2001; 15: 847-55. 
27) Health KV, Hogg Rs, Chan KJ, et al. Lipodystrophy associated 
morphological, cholesterol and triglyceride abnormalities in a 
population based HIV/AIDS treatment database. AIDS 2001; 15:         
231-9. 
28) Lichenstein KA, Ward DJ, Moorman AC, et al clinical assessment of 
HIV-associated lipodystrophy in an ambulatory population AIDS 
2001; 15: 1389-98. 
29) DANNER SA, CARR A, LEONARD JM, et al: A short term study of 
the safety pharmacokinetics, and efficacy of ritonavir, an inhibitor of 
HIV-2 protease. European – Australian collaborative Ritonvir study 
Group N. Engl. J. Med (1995) 333(23); 1528-1533. 
30) HATANO H, MILLER KD, YODER CP et al : metabolic and 
anthropometric consequences of interruption of highly active 
antiretroviral therapy AIDS (2000) 14(13) : 1935-1942. 
31) PURNELL JQ, ZAMBON A, KNOPP RH et al: Effect of ritonavir on 
lipids and post heparin lipase activities in normal subjects. AIDS 
(2000) 14(1) : 51-57. 
  
57
32) DUBE MP, EDMONDSON – MELANCON H, QIAN D, AQEEL R, 
JOHNSON D, BUCHANAN TA: Prospective evaluation of the effect 
of initiating indinavir – based therapy on insulin sensitivity and B-cell 
function in HIV – infected patients. J. Acquir immune. Defic. Syndr 
(2001) 27(2) : 130-134. 
33) NOOR MA, SENEVIRATNE T, AWEEKA FT et al: Indinavir 
acutely inhibits insulin – stimulated glucose disposal in humans: a 
randomized, place controlled study AIDS (2002) 16(5): F1-F8. 
34) BERNASCONI E, BOUBAKER K, JUNGHANS C et al 
Abnormalities of body fat distribution in HIV-infected persons treated 
with antiretroviral drugs: The swiss HIV cohort study J. Acquir. 
Immune Defic. Syndr (2002) 31(1) : 50-55. 
35) CARR A, SAMARAS K, THORISDOTTIR A, KAVFMANN GR, 
CHISHOLM DJ, COOPER DA: Diagnosis, prediction and natural 
course of HIV-1 protease – inhibitor – associated lipodystrophy, 
hyperlipidaemia, and diabetes mellitus; a cohort study. Lancet (1999) 
353 (9170); 2093-2099. 
36) ALDEEN T, WELLS C, HAY P, DAVIDSON F, LAV R; 
Lipodystrophy associated with nevirapine – containing anti-retroviral 
therapies AIDS (1999) 13(7) : 865-867. 
  
58
37) FEINGOLD KR, KRAUSS RM, PANG M, DOERRLER W, 
JENSEN P , GRUNFELD C: The hypertriglyceridaemia of acquired 
immunodeficiency syndrome is associated with an increased 
prevalence of low density lipoprotein subclass pattern B, J. clin. 
Endocrinol. Metab (1993) 76(6): 1423-127. 
38) GRUNFELD C, PANG M, DOERRLER W, SHIGENAGA JK, 
JENSEN P, FEINGOLD KR: Lipids, lipoproteins, triglyceride 
clearance, and cytokines in human immuno deficiency virus infection 
and the acquired immunodeficiency syndrome J. Clin Endocrinol 
metab (1992) 74(5): 1045-1052. 
39) MULLAMITHA SA, PAZARE AR: Study of lipid profile in human 
immunodeficiency virus infection J. Assoc. Physicians India (1999) 
47(6) : 622-624. 
40) SHOR-POSNER G, BASIT .A, LU Y et al; Hypocholesterolemia is 
associated with immune dysfunction in early human 
immunodeficiency virus -1 infection. AM-J-Med. (1993) 94(5):            
515-19 
41) GRUNFELD C, DOERRLER W, PANG M, JENSEN P. 
WEISGRABER KH, FEINGOLD KR: Abnormalities of 
  
59
apolipoprotein E in the acquired immunodeficiency syndrome J. Clin 
Endocrinol metab (1997)-82(11): 3734-3740. 
42) HELLERSTEIN MK, GRUNFELD C, WU K et al: Increased de novo 
hepatic lipogenesis in human immunodeficiency virus infection J. 
Clin Endocrinol Metab (1993) 76(3): 559-565. 
43) JAHOOR F, GAZZARD B, PHILLIPS G et al: The acute phase 
protein response to human immunodeficiency virus infection in 
human subjects AM J. Physiol (1999) 276(6 pt 1): E 1092-E1098. 
44) HADIGAN C, BORGONHA S, RABE J, YOUNG V, GRINSPOON 
S: Increased rates of lipolysis among human immunodeficiency virus 
infected mere receiving highly active antiretroviral therapy. 
Metabolism (2002) 51(9) : 1143-1147. 
45) DIXON JL, FURUKAWA S, GINSBERG HN: oleate stimulates 
secretion of apolipoprotein B – containing lipoproteins from Hep G2 
cells by inhibiting early intracellular degradation of apolipoprotein B 
J. Biol. Chem (1991) 266(8) 5080-5086. 
46) SINHA R, DUFOUR S, PETERSEN KF et al. Assessment of skeletal 
muscle triglyceride content  by (1) H nuclear magnetic resonance 
spectrophy in lean and obese adolescents; relationships to insulin 
  
60
sensitivity; total body fat, and central adiposity. Diabetes (2002) 
51(4); 1022-1027. 
47) MURATA H, HRUZ PW, MUECKLER M: The mechanism of 
insulin resistance caused by HIV – Protease inhibitor therapy J. Biol. 
Chem.(2000)275(27): 20251-20254. 
48) CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: 
Pathogenesis of HIV -1 protease inhibitor – associated peripheral 
lipodystrophy, hyperlipidaemia, and insulin resistance Lancent (1998) 
351(9119): 1881-1883. 
49) ROHLMANN A. GOTTHARDT M, HAMMER RE, HERZ J: 
Inducible inactivation of hepatic LRP gene by cre-mediated 
recombination confirms role of LRP in clearance of chylomicron 
remnants J. Clin.Invest (1998) 101(3): 689-695. 
50) SAXENA U, GOLD BERG IJ: Interaction of lipoprotein lipase with 
glycosaminoglycans and apolipoprotein CII: effects of free fatty acids, 
Biochim Biophys Acta (1990) 1043(2): 161-168. 
51) FAUVEL J, BONNET E, RUIDAVETS JB et al: An interaction 
between apo C – III variants and protease inhibitors contributes to 
high triglyceride / low HDL levels in treated HIV patients. AIDS 
(2001) 15(18); 2397-2406 
  
61
52) MOOSER V, CARR A: Antiretroviral therapy associated 
hyperlipidaemia in HIV disease.  curr. Opin. Lipidol (2001) 12(3): 
313-319. 
53) ZAERA MG, MIRO O, PEDROL E, et al Mitcochondrial 
involvement in antiretroviral therapy – related 
lipodystrophy.AIDS.2001;15:1643-51 
54) BEHRENS G, SCHMIDT HH, STOLL M, SCHMIDT RE: ApoE 
genotype and protease inhibitor – associated hyperlipidaemia Lancet 
(1999) 354(9172):76 
55) GRUNFELD C, DOERRLER W, PANG M, JENSEN P, 
WEISGRABER KH, FEINGOLD KR. Abnormalities of 
apolipoprotein E in the acquired immunodeficiency syndrome. J. Clin 
Engocrinlo. Metab. 1997; 82: 3734-40. 
56) BEHRENS G, SCHMIDT H, MEYER D, STOLL M, SCHMIDT RE. 
Vascular complications associated with use of HIV protease inhibitors 
lancet 1998; 351: 1958. 
57) HENRY K, MELROE H, HUEBSCH J, et al. severe premature 
coronary artery disease with protease inhibitors Lancet 1998; 351; 
1328. 
  
62
58) VittecoqD, Escart L, Monsuez II. Vascular complications associated 
with the use of HIV protease inhibitors Lancet. 1998; 351:1959. 
59) Eriksson U, opravil M, Amann FW, Schaffner A. is treatment with 
ritonavir a risk factor for myocardial infarction in HIV-infected 
patients? AIDS: 1998: 12:2079-80. 
60) Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men 
receiving protease inhibitors Ann Intern Med. 1999; 131: 548. 
61) Muise A, Arbess G. The risk of myocardial infarction in HIV-infected 
patients receiving HAART, a case report Int J STD AIDS 2001; 12-
612-3. 
62) KLEIN D, HURLEY L, QUESENBERRY C: Hospitalisations for 
CHD and MI among Northern California HIV + and HIV – men; 
additional follow up and changes in practice proceedings of the 12th 
conference on retrovirus and opportunistic infections. Boston, MA, 
USA (2005) Abstract No. 869. 
63) FRIIS – MOLLER N, SABIN CA, WEBER R et al combination 
antiretroviral therapy and the risk of myocardial infarction N. Engl. J. 
Med (2003) 349(21): 1993-2003. 
  
63
64) EGGER M, JUNGHANS C, FRIIS – MOLLER N, LUNDGREN JD: 
Highly active antiretroviral therapy and coronary heart disease ; the 
need for perspective AIDS (2001) 15 (suppl 5) S 193-S201 
65) BONNET D, AGGOUN Y, SEZEZEPANSKI I, BELLAL N, 
BLANCHE S: Arterial stiffness and endothelial dysfunction in HIV – 
infected children. AIDS (2004) 18(7) : 1037-1041. 
66) SHANKAR SS, DUBE MP: Clinical aspects of endothelial 
dysfunction associated with human immunodeficiency virus infection 
and antiretroviral agents cardiovasc Toxicol (2004) 4(3): 261-269. 
67) STEIN JH, KLEIN MA, BELLEHUMEUR JL et al: use of human 
immunodeficiency virus – 1 protease inhibitors is associated with 
atherogenic lipoprotein changes and endothelial dysfunction 
circulation (2001) 104(3) : 257-262. 
68) MARTINEZ E, ARRIBAS J, LOPEZ-ALDEGUER J: Factors 
associated with a high cardiovascular risk in HIV-infected patients in 
Spain: a multicenter, nationwide, cross-sectional study. Proceeding of 
the 12th Conference on Retroviruses and Opportunistic Infections, 
Boston, MA, USA (2005) Abstract no 870. 
69) SABIN CA, MORFELDT L, FRIIS-MOLLER N: Changes over time 
in the use of antiretroviral therapy and risk factors for cardiovascular 
  
64
disease in the D:A:D study. Proceedings of the 12th Conference on 
Retroviruses and Opportunistic Infections, Boston, MA, USA (2005) 
Abstract no 866. 
70) STEIN JH, WU Y, KAWABATA H, ILOEJE UH: Increased use of 
lipid-lowering therapy in patients receiving human immunodeficiency 
virus protease inhibitors. Am. J. Cardiol. (2003) 92(3):270-274. 
71) THIEBAUT R, URILLAC-LAVIGNOLLEV , BONNET F et al.: 
Change in atherosclerosis progression in HIV-infectred patients: 
ANRS Aquitaine Cohort, 1999-2004. AIDS (2005) 19(7):729-731. 
72) HULGAN T, STERLING TR, DAUGHERTY J, ARBOGAST PG, 
RAFANTI S, RAY W: Prescribing of contraindicated protease 
inhibitor and statin combinations among HIV- infected persons. J. 
Acquir. Immune. Defic. Syndr. (2005) 38(3): 277-282. 
73) Clumeck N, Goebel F, Rozenbaum W, et al. Simplificaiton with 
abacavir-based triple nucleoside therapy versus continued protease 
inhibitor-based highly active antiretroviral therapy in HIV-1-infected 
patients with undetectable plasma HIV-1 RNA. AIDS 2001:15:1517-
26. 
  
65
74) Martinez E, conget I, Lozano L, Casamitjana R, Gatell JM. Reversion 
of metaboli abnormalities after switching from HIV-1 protease 
inhibitors to nevirapine. AIDS 1999; 13:805-10. 
75) Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-
Lahoz J. Risks and benefits of replacing protease inhibitors by 
nevirapine in HIV-infected subjects under long-term successful triple 
combination therapy. AIDS 2000; 14:807-12. 
76) Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment 
simplification with nevirapine in protease inhibitor – experienced 
patients with HIV-asociated lipodystrophy: 1-year prospective follow-
up of a multicenter, randomized, controlled study. J Acquir Imune 
Defic Syndr 2001; 27:229-36. 
77) Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and 
clinical impact of switching from protease inhibitors to nevirapine or 
to efavirenz in patients with human immunodeficiency virus infection 
and long-lasting viral suppression. Clin Infect Dis 2002; 34:504-10. 
78) Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution 
in patients with lipodystrophy: a randomized, controlled, open-label, 
multicentre study. AIDS 2001; 15:1811-22. 
  
66
79) Raffi F, Bonner B, Ferre V, et al. Substitution of a nonnucleoside 
reverse transcriptase inhibitor for a protease inhibitor in the treatment 
of patients with undetectable plasma human immunodeficiency virus 
type 1 RNA. Clin Infect Dis 2000;31:1274-8. 
80) Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of 
HAART-associated insulin resistance and dyslipidemia after 
replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 
6:413-21. 
81) Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic 
lipoprotein profile in HIV-1 infected patients with lipodystrophy after 
replacing protease inhibitors by nevirapine. AIDS 2002; 16:1383-9.  
82) Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching 
from human immunodeficiency virus type 1 protease inhibitors to 
efavirenz in successfully treated adults with lipodystrophy. Clin Infect 
Dis 2000; 31: 1266-73. 
83) BRUNZELL J.P. BIERMANN EL. Chylomicronemia syndrome – 
interaction of genetic and acquired hypertriglyceridemia med clin orth 
Am. 1982; 66: 455-68. 
 
 
  
67
 
MASTER CHART 
S.NO. NAME AGE SEX CD4 
WHO 
STAGE TC TGL HDL GROUP
1 Narayanan 40 M 388 II 138 94 42 2 
2 Kavitha 42 F 368 II 226 211 40 2 
3 Parthasarathy 42 M 275 IV 176 112 50 2 
4 Moorthy 38 M 155 I 254 316 33 2 
5 Vijaya 43 F 142 III 159 269 42 2 
6 Joseph 33 M 42 III 115 76 58 2 
7 Mani 36 M 52 III 199 151 41 2 
8 Renganathan 63 M 162 III 251 441 36 2 
9 Shankar 34 M 17 II 212 412 35 2 
10 Venkatesan 36 M 138 IV 136 182 46 2 
11 Kutty 35 M 268 IV 217 287 38 2 
12 Lakshmi Sundari 47 F 325 II 186 350 36 2 
13 S.Kumar 33 M 433 II 194 100 45 2 
14 Gnanasekaran 42 M 233 III 126 249 242 2 
15 Sairabanu 38 F 288 III 150 517 47 2 
16 Gopalakrishnan 45 F 493 II 183 121 51 2 
17 Manickam 42 M 882 I 279 456 40 2 
18 Anbarasi 27 F 837 II 252 185 41 2 
19 Baby 30 F 423 I 214 125 44 2 
20 Parthasarathy 34 M 690 I 209 209 43 2 
21 Murugesan 61 M 209 I 165 320 50 2 
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22 Shankar 52 M 517 II 439 1365 44 2 
23 Sivakolunthu 56 M 570 II 167 355 46 2 
24 Ramesh 30 M 588 I 140 187 50 2 
25 Violet 44 F 303 IV 175 298 42 2 
26 Arumugam 39 M 795 I 131 167 50 2 
27 Sridhar 36 M 384 II 150 313 49 2 
28 Malligarani 34 F 254 I 183 553 48 2 
29 Anbarasan 36 M 420 I 136 210 45 2 
30 Rajamanickam 40 M 556 I 140 162 40 2 
31 Vijaya 34 F 384 II 150 313 49 2 
32 Ponnurangam 44 M 254 I 183 553 48 2 
33 Ramasamy 38 M 420 I 136 210 45 2 
34 Dhanalakshmi 32 F 556 I 140 162 40 2 
35 Mani 36 M 448 III 132 350 38 2 
36 Dhanasekar 38 M 119 IV 164 160 44 2 
37 Dhanabalan 36 M 113 IV 175 458 40 2 
38 Devakumar 32 M 289 III 210 240 42 2 
39 Neetha 38 F 86 II 180 186 50 2 
40 Chinnathai 27 F 446 III 120 382 42 2 
41 Latha 30 F 443 I 142 120 40 2 
42 Krishnamoorthy 30 M 295 II 110 268 41 2 
43 Sagayaraj 37 M 289 II 198 160 42 2 
44 Sugumaran 41 M 76 IV 246 129 42 2 
45 Venkatesan 34 M 171 IV 202 492 38 2 
46 Shanthi 28 F 297 III 182 152 46 2 
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47 Manickam 32 M 318 IV 138 110 40 2 
48 Vasantha Kumari 26 F 398 IV 168 312 42 2 
49 Babu 38 M 646 III 212 284 41 2 
50 Gunasekar 34 M 627 III 126 212 39 2 
51 Tamilselvi 32 F 480 I 160 130 44 1 
52 Kumar 40 M 366 II 196 152 40 1 
53 Anandan 36 M 420 I 150 140 42 1 
54 Devendran 32 M 588 II 126 160 46 1 
55 Srinivasan 35 M 257 II 184 148 40 1 
56 Vijayalakshmi 29 F 985 I 202 158 38 1 
57 Janarthanan 26 M 260 II 166 202 42 1 
58 Viji 35 F 580 I 192 210 40 1 
59 Rajasekar 41 M 299 II 206 160 41 1 
60 Mercy .P 29 F 726 I 240 198 42 1 
61 Lakshmi Sundari 23 F 625 I 160 130 44 1 
62 Manikandan 27 M 427 I 196 152 40 1 
63 
S. 
Santhanavairavan 26 M 726 I 156 140 42 1 
64 K.Balaji 34 M 444 I 192 260 40 1 
65 M. Manivannan 36 M 437 I 196 210 42 1 
66 Kasthuri 27 F 400 I 210 140 38 1 
67 S. Amudha 35 F 280 II 202 290 42 1 
68 Mala 30 F 461 I 200 202 40 1 
69 P. Balamani 40 M 447 II 196 142 42 1 
70 Saranya .K 25 F 306 I 182 168 42 1 
71 Devaki 39 F 564 I 220 192 38 1 
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72 Ravi 44 M 305 II 186 190 44 1 
73 Pushparaj 35 M 825 I 202 140 40 1 
74 Mayakrishnan 34 M 584 I 160 138 42 1 
75 K.Rekha 23 F 498 I 142 156 42 1 
76 Basheera 24 F 352 I 148 162 40 1 
77 Perumal 39 M 543 I 168 159 41 1 
78 S.Kumar 28 M 987 I 174 170 38 1 
79 V.Kasthuri 31 F 627 I 130 316 40 1 
80 Pencilliah 27 M 598 I 190 126 42 1 
81 Monica 27 F 747 I 120 130 42 1 
82 M.Mani 29 M 365 II 138 142 44 1 
83 G.Kumar 40 M 407 II 178 152 40 1 
84 Sathya 30 F 350 II 182 148 42 1 
85 Jayadha 30 F 468 I 198 122 42 1 
86 B.Usha 36 F 363 II 140 190 40 1 
87 Shankari 30 F 365 II 162 124 42 1 
88 T.Sumathy 29 F 961 I 156 136 40 1 
89 P.Srinivasan 28 M 436 I 182 130 42 1 
90 Damodharan 26 M 498 II 198 148 41 1 
91 K.Nagalingam 36 M 555 I 138 412 38 1 
92 D.Shanmugam 26 M 366 II 154 152 40 1 
93 A.Mani 42 M 476 I 188 162 42 1 
94 Narayani 45 F 377 II 202 180 40 1 
95 T.Amulu 20 F 461 I 149 420 38 1 
96 Prema .K 28 F 519 I 169 148 40 1 
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97 R.Rajeswari 22 F 1208 I 180 162 40 1 
98 Ramu 28 M 653 I 136 382 39 1 
99 Vimala 36 F 441 I 210 156 40 1 
100 Geetha 29 F 522 I 192 172 42 1 
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PROFORMA 
 
 
Name :     Age:     Sex: 
 
Address :       Occupation :  
 
 
 
 
 
Hospital No.  
 
 
Duration of Illness :  
(Since Diagnosis) 
 
 
 
Past History:  
  DM   / COPD / Drug intake etc.. 
  
  
Personal History: 
  Smoking / Alcohol intake / Drug abuse 
 
 
Treatment History : 
 
  HAART Therapy duration : 
 
  Drug combination  
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GENERAL PHYSICAL EXAMINATION  
 
 
 
Weight :     BMI : 
 
Height : 
 
P  I  CL   PE    LN 
 
Oral Candidiasis 
 
Herpes Zoster 
 
Vital Signs 
 
 Pulse   : 
  
 BP   : 
  
 Temperature :  
  
 Respiratory Rate : 
 
System Examination  
 
 CVS   : 
 
 Rs   :  
 
 Abdomen  : 
 
 CNS   : 
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Investigation  
 
Hemogram : TC  DC   HB   PCV 
  Platelets    ESR 
RFT:  Sugar   Urea   Creatinine 
LFT:  Bilirubin  SGOT  SGPT   SAP 
  T.Protein  Albumin 
Urine Routine  
 
ECG : 
CXR : 
ELISA  for HIV : 
CD4 Counts  : 
Lipid Profile  
 TC   TGL   HDL 
 
 
 
 
 
 
 
